ERBB2 and breast carcinoma: As demonstrated by retrospective analysis of randomized clinical trials and non-randomized studies, the 21-gene RS assay is invaluable in guiding treatment recommendations for patients with early stage, ER+/HER2- breast cancer [8–17, 24].